
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
11535 Sorrento Valley Road Suite 401
San Diego, CA 92121
San Diego, CA 92121
(858) 720-8797 |
info@attenuon.com |
www.attenuon.com |
Location: Single
Congr. District: 52
County: San Diego
Congr. District: 52
County: San Diego
Public Profile
Attenuon, L.L.C. is a pharmaceutical company seeking to develop a new generation of cancer therapeutics: organized around developing cancer therapeutics to disrupt cellular signaling processes to tumor growth and metastatsis. instead of poisoning cells, these therapies are designed to selectively disrupt cellular signaling processes important to tumor growth and metastasis (the spreading of tumors). Based on this approach, Attenuon hopes to develop therapies that will be effective against many types of cancer, produce few side effects, be less prone to acquired drug resistance, be suitable for long-term use, and work well with existing therapies. The firm offered ATN-224 that disrupts signaling pathways involved in tumor growth, angiogenesis, and metastasis, including those mediated by multiple kinases, as well as NF-kappaB by inhibiting the enzyme superoxide dismutase; and ATN-161, a five-amino acid peptide derived from fibronectin. Coincident with its SBIR involvement. it was announced that the Japanese firm Kirin Brewery and its US subsidiary Gemini Science would work with Attenuon to develop fully human monoclonal antibody (MAb) candidates as cancer therapeutic and diagnostic agents.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
20-24Revenue Range
2M-2.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
15-19Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2004 | 1 | NIH | $282,980 | |
Project Title: A targeted peptide for PET imaging of cancer | ||||
2002 | 1 | NIH | $100,000 | |
Project Title: Minimization of an anti-angiogenic protein |
Key People / Management
David E Shaw -- President
Fernando Donate
Fernando Donate
Company News
There are no news available.